Σύγκριση μεθόδων

	Συσχέτιση In Vitro-In Vivo	Κινητική Michaelis-Menten
Πεδίο	Φαρμακολογία	Φαρμακολογία
Οικογένεια	Process / pipeline	Process / pipeline
Έτος προέλευσης	1995	1913
Δημιουργός	Gordon Amidon	Leonor Michaelis and Maud Menten
Τύπος	bioavailability prediction	mechanistic model
Θεμελιώδης πηγή	Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12(3), 413-420.	Michaelis, L., & Menten, M. L. (1913). Die Kinetik der Invertinwirkung. Biochemische Zeitschrift, 49, 333-369.
Εναλλακτικές ονομασίες	IVIVC	MM kinetics, Michaelis constant, Vmax
Συναφείς	3	2
Σύνοψη	IVIVC is a mathematical relationship between in vitro and in vivo properties of a drug, developed to predict oral bioavailability from dissolution data. Introduced by Amidon and colleagues in the 1995 Biopharmaceutics Classification System, it bridges laboratory measurements and clinical outcomes to streamline drug development.	Michaelis-Menten kinetics describes the rate of enzyme-catalyzed reactions as a function of substrate concentration. Developed by Leonor Michaelis and Maud Menten in 1913, this foundational framework models enzyme catalysis through the rapid-equilibrium approximation and enables prediction of drug metabolism rates in pharmacokinetics.